[Recommendations for the prevention of respiratory syncytial virus in high-risk pediatric groups].
Janković
Borisav
B
Institut za zdravstvenu zastitu majke i deteta Srbije, Dr Vukan Cupić, Beograd, Srbija.; tUniverzitetska derija klinika, Beograd, Srbija; *Institut za neonatologiju, Beograd, Srbija. borisav.jan@sbb.rs
Minić
Predrag
P
Maglajlić-Djukić
Svjetlana
S
Prekajski
Niveska
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000517:prevention & control*; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab